AMD
47
5
7
22
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
10.6%
5 terminated out of 47 trials
81.5%
-5.0% vs benchmark
9%
4 trials in Phase 3/4
27%
6 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (47)
Retinal Clinical Assessment With AI-derived Quantitative Information
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
Cell Collection to Study Eye Diseases
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD
Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natural History Cohort
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration
Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SINE)
Phase 2/3 Study of ALK-001 in Geographic Atrophy
A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)
Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
Retinal Imaging Using NOTAL-OCT V3.0
Dual Wavelength OCT
X-82 to Treat Age-related Macular Degeneration
Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.